# STOCKHOLM 1.0
#=GF ID   Cbl_N3
#=GF AC   PF02762.18
#=GF DE   CBL proto-oncogene N-terminus, SH2-like domain
#=GF AU   Bateman A;0000-0002-6982-4660
#=GF AU   Mian N;0000-0003-4284-4749
#=GF AU   Griffiths-Jones SR;0000-0001-6043-807X
#=GF SE   Pfam-B_3949 (release 5.2)
#=GF GA   25.00 25.00;
#=GF TC   25.10 27.30;
#=GF NC   23.50 24.90;
#=GF BM   hmmbuild HMM.ann SEED.ann
#=GF SM   hmmsearch -Z 75585367 -E 1000 --cpu 4 HMM pfamseq
#=GF TP   Domain
#=GF WK   Cbl_TKB_domain
#=GF CL   CL0541
#=GF RN   [1]
#=GF RM   10078535
#=GF RT   Structure of the amino-terminal domain of Cbl complexed to its
#=GF RT   binding site on ZAP-70 kinase 
#=GF RA   Meng W, Sawasdikosol S, Burakoff SJ, Eck MJ; 
#=GF RL   Nature 1999;398:84-90.
#=GF DR   INTERPRO; IPR014742;
#=GF DR   SCOP; 1b47; fa;
#=GF DR   SO; 0000417; polypeptide_domain;
#=GF CC   Cbl is an adaptor protein that binds EGF receptors (or other
#=GF CC   tyrosine kinases) and SH3 domains, functioning as a negative
#=GF CC   regulator of many signaling pathways. The N-terminal domain is
#=GF CC   evolutionarily conserved, and is known to bind to phosphorylated
#=GF CC   tyrosine residues. The so called N-terminal domain is actually 3
#=GF CC   structural domains, of which this is the C-terminal SH2 domain.
#=GF SQ   10
#=GS A9UYU0_MONBE/228-313      AC A9UYU0.1
#=GS F2UL73_SALR5/245-330      AC F2UL73.1
#=GS B3RTT8_TRIAD/260-345      AC B3RTT8.1
#=GS A0A0D2WMR8_CAPO3/283-368  AC A0A0D2WMR8.1
#=GS T1FF20_HELRO/104-183      AC T1FF20.1
#=GS G4VQX3_SCHMA/215-302      AC G4VQX3.1
#=GS A0A8R1UEY1_PRIPA/256-341  AC A0A8R1UEY1.1
#=GS Q6ABG8_CAEEL/256-341      AC Q6ABG8.1
#=GS G3W1H1_SARHA/263-348      AC G3W1H1.2
#=GS A0A8M1NHR6_DANRE/246-331  AC A0A8M1NHR6.1
A9UYU0_MONBE/228-313                 RHPAYQAFITYDEVEATLSNHRHK..PGSYVFRLSCTRLGQWAIGFVAKDGQIVQTIPQSKSLYQALIDGAEQGTFLYPNGEDANPDI
F2UL73_SALR5/245-330                 NHPAYKAFITYDEVEAILRHHLHR..PGSYVYRLSCTRLGQWAIGFVTRAGKIVQTIPQNKSLYQALLDGVEERLYLYPDGKNVQLDL
B3RTT8_TRIAD/260-345                 SHPGYAAFLTYDDAKNALEPFLDR..PGSYIFRLSCTRLGQWAIAYVEESRNVVQTIPNNKPLRQALIDGFNDGIYLYPAGNDANPDL
A0A0D2WMR8_CAPO3/283-368             THPAYQAYMTYDEVNTVLKPFVNK..PGSYVFRLSCTRLGQWAIGYVNAEKKVVQTIPNTKSLYQALIDGSVDGTFKYPMGQDDNPDI
T1FF20_HELRO/104-183                 SHPGYVAFMTYDEVKAMLAKFKDK..PG......SCTRLGQWAIGYVTKNNEILQTIPQNKSLGQALIDGQKEKYYLYPAGQAHNPNI
G4VQX3_SCHMA/215-302                 LHPGYMAFMTYDQVKGVLKRYCTHPGPGTYIFRLSCTKLGQWAIGYITQELKIVQTIIQNKSLAQALVDGEREGFYLYPNGKPSPTTL
A0A8R1UEY1_PRIPA/256-341             DHKGFVAFLTYDEVRKRLDRFINK..PGSYVFRMSCTRLGQWAIGYVAPDGKIYQTIPQNKSLIQALHEGGREGFYLWPDGNDKDMDL
Q6ABG8_CAEEL/256-341                 AHPGYCAFLTYDEVKKRLEKLTKK..PGSYIFRLSCTRPGQWAIGYVAPDGKIYQTIPQNKSLIQALHEGHKEGFYIYPNGRDQDINL
G3W1H1_SARHA/263-348                 THPGYMAFLTYDEVKARLQKFIHK..PGSYIFRLSCTRLGQWAIGYVTADGNILQTIPHNKPLFQALIDGFREGFYLFPDGRNQNPDL
A0A8M1NHR6_DANRE/246-331             THPGYMAFLTYDQVKARLEHYRHR..PGSYIFRLSCTQMGQWAIGHVTSDGSIVQTIPQNTPLYQALIQGFREGCYLYPDGRDVNPDL
#=GC seq_cons                        sHPGYhAFlTYDEVKutLc+ahcK..PGSYlFRLSCTRLGQWAIGYVsp-GcIVQTIPQNKSLhQALIDGt+EGhYLYPsGcDsNPDL
